These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 5118683)

  • 1. Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor.
    Dano K
    Cancer Chemother Rep; 1971 Apr; 55(2):133-41. PubMed ID: 5118683
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivo.
    Danø K
    Cancer Chemother Rep; 1972 Jun; 56(3):321-6. PubMed ID: 19051490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo.
    Dano K
    Cancer Chemother Rep; 1972 Dec; 56(6):701-8. PubMed ID: 4660629
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
    Skovsgaard T
    Cancer Chemother Rep; 1975; 59(2 Pt 1):301-8. PubMed ID: 1149008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Dec; 38(12):4722-7. PubMed ID: 719649
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytogenetic investigations on a Ehrlich ascites tumor, and four sublines resistant to daunomycin, adriamycin, vincristine and vinblastine.
    Hasholt L; Dan0 K
    Hereditas; 1974; 77(2):303-10. PubMed ID: 4141349
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Chemother Pharmacol; 1979; 2(1):43-7. PubMed ID: 498419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytological and cytochemical analysis of Ehrlich ascites tumor cells treated with daunomycin.
    Bassleer R; Goessens G; Lepoint A; Desaive C; Kinet-Denoel C
    Beitr Pathol; 1973 Dec; 150(3):261-73. PubMed ID: 4771313
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.
    Skovsgaard T
    Cancer Res; 1978 Jun; 38(6):1785-91. PubMed ID: 647687
    [No Abstract]   [Full Text] [Related]  

  • 10. [Biochemistry of antileukemic drugs].
    Bollag W
    Schweiz Med Wochenschr; 1970 Feb; 100(7):310-4. PubMed ID: 4908606
    [No Abstract]   [Full Text] [Related]  

  • 11. [RNA polymerase activity of Ehrlich ascites carcinoma nuclei in relation to the mechanism of action of N-alkyl-N-nitrosourea].
    Mitskevich LG; Rozet EG; Kukushkina GV; Gorbacheva LB
    Biokhimiia; 1972; 37(4):851-4. PubMed ID: 4634310
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapeutic effects of compound 593A (NSC-135758) on mouse leukemias and some transplanted animal tumors.
    Tarnowski GS; Schmid FA; Hutchison DJ; Stock CC
    Cancer Chemother Rep; 1973 Feb; 57(1):21-7. PubMed ID: 4704098
    [No Abstract]   [Full Text] [Related]  

  • 13. Daunomycin pharmacological activity at the cellular level.
    Di Marco A
    Pathol Biol; 1967 Oct; 15(19):897-902. PubMed ID: 4297686
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of cancer chemotherapy drugs on platelet aggregation.
    Hiçsönmez G
    Turk J Pediatr; 1974 Jan; 16(1):1-7. PubMed ID: 4460325
    [No Abstract]   [Full Text] [Related]  

  • 15. Survival time of mice bearing Ehrlich ascites tumor, with special reference to the effect of hydrocortisone administration.
    Kodama M; Amo H; Kodama T
    J Natl Cancer Inst; 1970 May; 44(5):1055-64. PubMed ID: 5514471
    [No Abstract]   [Full Text] [Related]  

  • 16. The mechanism of action of methotrexate. II. Augmentation by vincristine of inhibition of deoxyribonucleic aic synthesis by methotrexate in Ehrlich ascites tumor cells.
    Goldman ID; Fyfe MJ
    Mol Pharmacol; 1974 Mar; 10(2):275-82. PubMed ID: 4859543
    [No Abstract]   [Full Text] [Related]  

  • 17. Combinations of 6-mercaptopurine (NSC-755) and 6-(methylmercapto)purine ribonucleoside (NSC-40774) in therapy of Ehrlich ascites carcinoma.
    Wang MC; Simpson AI; Paterson AR
    Cancer Chemother Rep; 1967 Jun; 51(3):101-9. PubMed ID: 6043733
    [No Abstract]   [Full Text] [Related]  

  • 18. Lectin staining patterns of plasma membranes of daunorubicin and vincristine resistant Ehrlich ascites tumour cells.
    Sehested M; Skovsgaard T
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1988; 54(6):366-70. PubMed ID: 2453973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of cyclophosphamide and 1-methylnitrosourea on Ehrlich carcinoma transplanted in different sites. Correlation between drug level and tumor inhibition.
    Bossi A; Colombo T; Donelli MG; Garattini S
    Biochem Pharmacol; 1975 Jan; 24(1):21-6. PubMed ID: 1122258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.